Quinazoline derivatives as src tyrosine kinase inhibitors

Details Quinazoline derivatives as src tyrosine kinase inhibitors Quinazoline derivatives as src tyrosine kinase inhibitors

C - Chemistry, Metallurgy

07

D

C07D 491/04 (2006.01) A61K 31/517 (2006.01) A61P 35/00 (2006.01) C07D 519/00 (2006.01)

Patent

CA 2503371

The invention concerns quinazoline derivatives of Formula (I): (A chemical formula should be inserted here - please see paper copy enclosed herewith) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)2 group wherein each R2 group is hydrogen or (1-8C) alkyl, m is 0, 1, 2 or 3, each R1 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, n is 0, 1, 2 or 3, and each R3 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, or pharmaceutically-acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

L'invention concerne des dérivés de quinazoline de formule (I) dans laquelle : Z représente O, S, SO, SO¿2?, ou un groupe N(R?2¿) ou C(R?2¿)¿2 ?où chaque groupe R?2 ¿représente hydrogène ou alkyle (1-8C), m représente 0, 1, 2 ou 3 ; chaque groupe R?1¿ est sélectionné parmi halogène, alkyle (1-8C), alkoxy(1-6C) et les autres composés définis dans la description ; n représente 0, 1, 2 ou 3, et chaque groupe R?3¿ est sélectionné parmi halogène, alkyle(1-8C), alkoxy(1-6C) et les autres composés définis dans la description, ou des sels pharmaceutiquement acceptables de ceux-ci. L'invention concerne également les procédés de préparation de ces dérivés ou de leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques contenant ces dérivés ou leurs sels pharmaceutiquement acceptables, et leur utilisation dans la production d'un médicament à utiliser comme agent anti-invasif dans la maîtrise et/ou le traitement d'une maladie de tumeur solide.

Affiliated with

Also associated with

Rating

Quinazoline derivatives as src tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinazoline derivatives as src tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives as src tyrosine kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1892348